The Effect of Sodium Lauryl Sulfate on the Oral Absorption of Fexofenadine in Humans
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Area under the plasma concentration versus time curve (AUC) of Fexofenadine
研究概览
简要总结
The purpose of this study is to determine if sodium lauryl sulfate (SLS), a non-drug ingredient commonly added in drug products, affect absorption of drugs that are given together with the ingredient. Investigators want to find out if drug absorption is different in people taking the drug alone compared to people taking the drug with low and high amounts of sodium lauryl sulfate at the same time.
详细描述
This is a single-center, randomized, double-blind, 3-period crossover trial. Participants will be randomized to receive a Control capsule (fexofenadine single agent) under Treatment Arm 1 or a Test 1 capsule (fexofenadine and 3 mg SLS) under Treatment Arm 2 or Test 2 capsule (fexofenadine and 30 mg SLS) under Treatment Arm 3. Investigators will assess the effect of SLS on the absorption of fexofenadine by measuring SLS and fexofenadine concentrations in plasma and stool samples and determine the change in AUC (area under the curve), Cmax and other pharmacokinetic parameters, between Treatment Arms 2 or 3 and Treatment Arm 1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers of all ethnic groups and races.
- •Male and females between the ages of 18-64 years old, inclusive.
- •Subjects who are willing to avoid ingestion of fruit juices and citrus bioflavonoids, such as grapefruit extract, hesperidin supplement and naringin supplement, for a period extending from one week prior to the initiation of the study until its completion.
- •Written informed consent obtained from the subject and ability for subject to comply with the requirements of the study.
排除标准
- •Subjects with extreme obesity (BMI > 35).
- •Subjects who are allergic to fexofenadine or SLS.
- •Subjects who have hemoglobin level lower than 12 g/dL.
- •Subjects who are pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
- •Subjects with chronic constipation.
- •Subjects consuming types of food and supplements with the potential to interfere with the study objectives as judged by the Investigator.
- •Subjects taking any drugs, especially known OATP2B1 substrates (aliskiren, atenolol, celiprolol, fexofenadine, rosuvastatin and ticlopidine, etc.) except birth control hormonal medications.
- •Subjects with a condition, disease, or abnormality that in the opinion of the Investigator would compromise the safety of the subject or the quality of the data.
- •Subjects with any disease affecting or impairing the function of the liver, kidney, or heart.
- •Subjects with gastrointestinal disease, gastrointestinal disorder, or gastrointestinal surgery.
- •Subjects with known infection with HIV, Hepatitis B or Hepatitis C (as determined by questionnaire, no laboratory diagnostics concerning these diseases will be performed within the present study). Volunteers who are cured of past Hepatitis C infection are eligible to participate with a doctor's approval letter.
- •Subjects who are smokers or have smoked in the past year and/or have smoked or ingested THC/marijuana in the past week, or who are unwilling to comply throughout the study period.
- •Alcohol use on average > 2 servings/day or > 14 servings/wk (Serving size: 12oz beer/4oz wine/2oz hard liquor) in the past week or self-reported binge drinking.
- •Subjects who are currently receiving any investigational agent or who have received any investigational agents within a period of 5 half-lives of the agent prior to the initiation of the current study.
- •Subjects who have donated whole blood within 8 weeks prior to study initiation or plan to donate blood during the study period.
- •Non-English speaking.
- •Subjects with abnormal laboratory results at Screening Visit as judged by the Investigator or study physician.
研究组 & 干预措施
Fexofenadine without SLS
Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride and 101 mg microcrystalline cellulose
干预措施: Fexofenadine Hydrochloride without sodium lauryl sulfate (Drug)
Fexofenadine and 3 mg SLS
Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 3 mg SLS and 101 mg microcrystalline cellulose
干预措施: Fexofenadine Hydrochloride with sodium lauryl sulfate (Drug)
Fexofenadine and 30 mg SLS
Participants will be administered by mouth with a capsule containing 120 mg fexofenadine hydrochloride, 30 mg SLS and 101 mg microcrystalline cellulose
干预措施: Fexofenadine Hydrochloride with sodium lauryl sulfate (Drug)
结局指标
主要结局
Area under the plasma concentration versus time curve (AUC) of Fexofenadine
时间窗: 0-48 hours
To determine whether SLS decreases the fexofenadine area under the curve (AUC) between Fexofenadine + 3 mg SLS or Fexofenadine + 30 mg SLS and Fexofenadine only.
Maximum Plasma Concentration (Cmax) of Fexofenadine
时间窗: 0-48 hours
To determine whether SLS decreases the fexofenadine Cmax between Fexofenadine + 3 mg SLS or Fexofenadine + 30 mg SLS and Fexofenadine only.
次要结局
- Sodium lauryl sulfate stool amount(0-48 hours)
- Sodium lauryl sulfate plasma concentration(0-48 hours)
- Fexofenadine stool amount(0-48 hours)